Role of Tumor-Associated Macrophages in Breast Cancer Immunotherapy DOI Creative Commons
Yan He, Quan Liu,

Zhuo-wa Luo

et al.

Frontiers in Bioscience-Landmark, Journal Year: 2025, Volume and Issue: 30(4)

Published: April 23, 2025

Breast cancer (BC) is the second leading cause of death among women worldwide. Immunotherapy has become an effective treatment for BC patients due to rapid development medical technology. Considerable breakthroughs have been made in research, marking beginning a new era treatment. Among them, various immunotherapies such as immune checkpoint inhibitors (ICIs), vaccines, and adoptive cell transfer are good prospects. The tumor microenvironment (TME) plays crucial role determining outcomes immunotherapy. Tumor-associated macrophages (TAMs) key component TME, with immunomodulatory effect closely related evasion cells, thereby affecting malignant progression. TAMs also significantly affect therapeutic ICIs (such programmed 1/programmed ligand 1 (PD-1/PD-L1) inhibitors). composed multiple heterogeneous subpopulations, including M1 phenotypes (M1) M2 (M2). Furthermore, they mainly play M2-like moderate variety harmful consequences angiogenesis, immunosuppression, metastasis. Therefore, area focus therapies. However, several immunotherapy studies demonstrated that only small number solid cancers, still faces relevant challenges tumors. This review explores immunotherapy, summarizing their involvement development. It explains classification functions TAMs, outlines current approaches combination therapies, discusses potential strategies immuno-oncology treatments.

Language: Английский

Bridging epigenomics and tumor immunometabolism: molecular mechanisms and therapeutic implications DOI Creative Commons
Xiaowen Xie, Weici Liu, Zhiyuan Yuan

et al.

Molecular Cancer, Journal Year: 2025, Volume and Issue: 24(1)

Published: March 8, 2025

Epigenomic modifications—such as DNA methylation, histone acetylation, and methylation—and their implications in tumorigenesis, progression, treatment have emerged a pivotal field cancer research. Tumors undergo metabolic reprogramming to sustain proliferation metastasis nutrient-deficient conditions, while suppressing anti-tumor immunity the tumor microenvironment (TME). Concurrently, immune cells within immunosuppressive TME adaptations, leading alterations function. The complicated interplay between metabolites epigenomic modulation has spotlighted significance of regulation immunometabolism. In this review, characteristics modification associated with tumors are systematically summarized alongside regulatory roles Classical emerging approaches delineated broaden boundaries research on crosstalk immunometabolism epigenomics. Furthermore, we discuss potential therapeutic strategies that target modulate modifications, highlighting burgeoning synergy therapies immunotherapy promising avenue for treatment.

Language: Английский

Citations

1
Single-cell RNA sequencing elucidates cellular plasticity in esophageal small cell carcinoma following chemotherapy treatment DOI Creative Commons
Qinkai Zhang, Ziyu Gao, Ru Qiu

et al.

Frontiers in Genetics, Journal Year: 2025, Volume and Issue: 15

Published: Jan. 9, 2025

Small cell carcinoma of the esophagus (SCCE) is a rare and aggressively progressing malignancy that presents considerable clinical challenges.Although chemotherapy can effectively manage symptoms during earlystages SCCE, its long-term effectiveness notably limited, with theunderlying mechanisms remaining largely undefined. In this study, weemployed single-cell RNA sequencing (scRNA-seq) to analyze SCCE samplesfrom single patient both before after treatment. Our analysisrevealed significant cellular plasticity alterations in tumormicroenvironment's composition. Notably, we observed an increase intumor diversity coupled reductions T cells, B myeloid-likecells. The pre-treatment samples predominantly featured cells amiddle transitional state, while post-treatment exhibited expandedpresence terminal, initial-to-terminal (IniTerm), universally alteredstates. Further analysis highlighted dynamic interactions between tumor andimmune changes detected key signaling pathways, suchas TIGIT-PVR MDK-SDC4. This study elucidates complex dynamics cellplasticity following chemotherapy, providing new insights identifyingpotential therapeutic targets enhance treatment efficacy.

Language: Английский

Citations

0
Hi-C profiling in tissues reveals 3D chromatin-regulated breast tumor heterogeneity informing a looping-mediated therapeutic avenue DOI

Lavanya Choppavarapu,

Kun Fang, Tianxiang Liu

et al.

Cell Reports, Journal Year: 2025, Volume and Issue: 44(4), P. 115450 - 115450

Published: March 18, 2025

Language: Английский

Citations

0
Role of Tumor-Associated Macrophages in Breast Cancer Immunotherapy DOI Creative Commons
Yan He, Quan Liu,

Zhuo-wa Luo

et al.

Frontiers in Bioscience-Landmark, Journal Year: 2025, Volume and Issue: 30(4)

Published: April 23, 2025

Breast cancer (BC) is the second leading cause of death among women worldwide. Immunotherapy has become an effective treatment for BC patients due to rapid development medical technology. Considerable breakthroughs have been made in research, marking beginning a new era treatment. Among them, various immunotherapies such as immune checkpoint inhibitors (ICIs), vaccines, and adoptive cell transfer are good prospects. The tumor microenvironment (TME) plays crucial role determining outcomes immunotherapy. Tumor-associated macrophages (TAMs) key component TME, with immunomodulatory effect closely related evasion cells, thereby affecting malignant progression. TAMs also significantly affect therapeutic ICIs (such programmed 1/programmed ligand 1 (PD-1/PD-L1) inhibitors). composed multiple heterogeneous subpopulations, including M1 phenotypes (M1) M2 (M2). Furthermore, they mainly play M2-like moderate variety harmful consequences angiogenesis, immunosuppression, metastasis. Therefore, area focus therapies. However, several immunotherapy studies demonstrated that only small number solid cancers, still faces relevant challenges tumors. This review explores immunotherapy, summarizing their involvement development. It explains classification functions TAMs, outlines current approaches combination therapies, discusses potential strategies immuno-oncology treatments.

Language: Английский

Citations

0